| Company Name: |
Nanjing Dulai Biotechnology Co., Ltd.
|
| Tel: |
025-846993838003-8003 18013301590 |
| Email: |
njduly@126.com |
| Products Intro: |
Product Name:ONO-RS-082
CAS:99754-06-0
Purity:>=98% Package:100mg
|
2-(P-AMYLCINNAMOYL)AMINO-4-CHLOROBENZOIC ACID manufacturers
- ONO-RS-082
-
- $35.00 / 2mg
-
2026-01-05
- CAS:99754-06-0
- Min. Order:
- Purity: 99.35%
- Supply Ability: 10g
|
| | 2-(P-AMYLCINNAMOYL)AMINO-4-CHLOROBENZOIC ACID Basic information |
| Product Name: | 2-(P-AMYLCINNAMOYL)AMINO-4-CHLOROBENZOIC ACID | | Synonyms: | 2-(P-AMYLCINNAMOYL)AMINO-4-CHLOROBENZOIC ACID;ONO-RS-082;2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid;2-[[(E)-4-Pentylcinnamoyl]amino]-4-chlorobenzoic acid sodium salt;4-Chloro-2-[[1-oxo-3-(4-pentylphenyl)-2-propen-1-yl]amino]-benzoic acid;(E)-4-chloro-2-(3-(4-pentylphenyl)acrylamido)benzoic acid;(E)-4-chloro-2-(3-(4-pentylphenyl)acrylamido)benzoic acid(WXC06363);4-chloro-2-[[(E)-3-(4-pentylphenyl)prop-2-enoyl]amino]benzoic acid | | CAS: | 99754-06-0 | | MF: | C21H22ClNO3 | | MW: | 371.86 | | EINECS: | | | Product Categories: | | | Mol File: | 99754-06-0.mol |  |
| | 2-(P-AMYLCINNAMOYL)AMINO-4-CHLOROBENZOIC ACID Chemical Properties |
| Melting point | 175-177℃ | | storage temp. | room temp | | solubility | DMSO: ≥20mg/mL | | form | powder | | color | white | | Sensitive | Light Sensitive | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | | InChI | 1S/C21H22ClNO3/c1-2-3-4-5-15-6-8-16(9-7-15)10-13-20(24)23-19-14-17(22)11-12-18(19)21(25)26/h6-14H,2-5H2,1H3,(H,23,24)(H,25,26)/b13-10+ | | InChIKey | MDVFITMPFHDRBZ-JLHYYAGUSA-N | | SMILES | Clc1cc(c(cc1)C(=O)O)NC(=O)\C=C\c2ccc(cc2)CCCCC |
| Hazard Codes | N | | Risk Statements | 50 | | Safety Statements | 61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 2 | | HazardClass | 9 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Acute 1
Aquatic Chronic 1 |
| | 2-(P-AMYLCINNAMOYL)AMINO-4-CHLOROBENZOIC ACID Usage And Synthesis |
| Description | ONO-RS-082 (99754-06-0) is a reversible inhibitor of Ca2+-independent phospholipase A2(PLA2), IC50=7 μM for guinea pig lung PLA2.1Inhibits epinephrine-induced thromboxane production in platelets.1Inhibition of PLA2by ONO-RS-032 disrupts endosome tubule formation and maintenance of the Golgi complex.2-4Prevents Xenopus oocyte maturation at stage V.5 | | Uses | ONO-RS-082 is a potent PLA2 and epinephrine inhibitor.ONO-RS-082 is a phospholipase inhibitor. | | in vitro | previous study found that human platelets stimulated by epinephrine led to enhanced turnover of phosphatidylinositol 4,5-bisphosphate, accumulated inositol trisphosphate, diacylglycerol, and phosphatidic acid, indicating stimulation of phospholipase c. it was shown that these responses could be completely blocked by inhibitors of alpha 2-adrenergic receptors including ono-rs-082 or removal of fibrinogen. in addition, epinephrine could evoked an increased turnover of ester-linked arachidonic acid in aspirin treated platelets that was inhibited by ono-rs-082 or the absence of fibrinogen. moreover, it was found that ono-rs-082 at 3.5 μm was able to inhibit epinephrine-stimulated thromboxane production in human platelets. ono-rs-082 could also disrupt endosome tubule formation and maintenance of the golgi complex [1]. | | in vivo | In vivo long-term activation of KCNK3 by ONO-RS-082 (50 mg/kg/day; preventive treatment, day 0 to day 21) reduces the development of PH in the MCT-PH model[4].
In contrast, in vivo short-term KCNK3 activation by ONO-RS-082 (curative treatment) fails to reduce PH symptoms, which is attributed to the complete loss of KCNK3 expression in MCT-PH rats at days 14 to 21[4]. | Animal Model: | MCT- pulmonary hypertension (PH) rat model[4] | | Dosage: | 50 mg/kg/day | | Administration: | | | Result: | Reduced the development of PH in the MCT-PH model for long-term.
|
| | References | [1] H S BANGA. Activation of phospholipases A and C in human platelets exposed to epinephrine: role of glycoproteins IIb/IIIa and dual role of epinephrine.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83 23: 9197-9201. DOI:10.1073/pnas.83.23.9197
[2] P. DE FIGUEIREDO. Inhibition of Transferrin Recycling and Endosome Tubulation by Phospholipase A2 Antagonists*[J]. The Journal of Biological Chemistry, 2001, 27 1: 47361-47370. DOI:10.1074/jbc.m108508200
[3] JOHN A SCHMIDT. A role for phospholipase A2 activity in membrane tubule formation and TGN trafficking.[J]. Traffic, 2010, 11 12: 1530-1536. DOI:10.1111/j.1600-0854.2010.01115.x
[4] MARIE E BECHLER William J B. Gβ1γ2 activates phospholipase A2-dependent Golgi membrane tubule formation.[J]. Frontiers in Cell and Developmental Biology, 2014, 2 4: 0004. DOI:10.3389/fcell.2014.00004
[5] AZHARUL ISLAM . The distinct stage-specific effects of 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid on the activation of MAP kinase and Cdc2 kinase in Xenopus oocyte maturation[J]. Cellular signalling, 2005, 17 4: Pages 507-523. DOI:10.1016/j.cellsig.2004.09.011 |
| | 2-(P-AMYLCINNAMOYL)AMINO-4-CHLOROBENZOIC ACID Preparation Products And Raw materials |
|